News
GLP-1, Serena Williams and Zepbound
Digest more
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Zacks.com on MSN1d
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes ...
Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately $14.7 billion, up about 30% YoY, and adjusted EPS of $5.
A new imaging approach reveals how dual agonist drugs like tirzepatide act on the pancreas and brain to regulate blood sugar and appetite.
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...
In a head-to-head comparison of the two GLP-1 drugs, adults living with obesity or overweight who were taking Zepbound, the brand name for tirzepatide, lost more than 20% of their weight on ...
Zepbound is about 20% cheaper than competing drug Wegovy, which may help some Americans save money. Still, at over $1,000 a month, the drug is unaffordable for many.
Medindia on MSN16d
Zepbound Approved as First Drug for Sleep Apnea in Obese Adults
Zepbound approved for treating moderate to severe obstructive sleep apnea in adults with obesity, showing improvement in ...
In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback